Journal article · 2015 · Open access

Pharmacogenetics in clinical practice: Challenges and opportunities

Gordana Dragović, Nada Dolić, Božana Dimitrijević, Milan Jovanović, Marko Barović, Djordje Jevtović

Medicinska istrazivanja, 49(3), 26–32 · Published 1 January 2015 · DOI 10.5937/medist1501026d

Open full textCite this paper

In brief

“Pharmacogenetics in clinical practice: Challenges and opportunities” is a 2015 journal article by Gordana Dragović and 5 co-authors, published in Medicinska istrazivanja. OpenAlex counts 0 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at Medicinska istrazivanja.

Citations
0
References
49
Authors
6

Abstract

Pharmacogenetics studies the influence of genetic variation on drug response, while pharmacogenomics is a genome-wide and multifactorial extension of the term pharmacogenetics. Both pharmacogenetics and pharmacogenomics are the backbones of the concept called personalized medicine. Although a "personalized" approach has always been a goal of good medical practice, there is a new aspect of the extensive use of molecular data to tailor drug therapy to an individual patient, in order to maximize therapeutic benefit and minimize adverse events. The main causes of inter-individual variability in a patient are genetic variations in genes responsible for enzymes synthesis, which participate in absorption, distribution, metabolism and excretion (ADME system) of drugs. So, all patients can be classified in four groups, according to their genotype: slow metabolizers, intermediate metabolizers, ul-trafast metabolizers and extensive metabolizers who are most frequent and are considered to be a standard group of patients. The group of most essential metabolism enzymes is represented by a superfamily of cytochrome P450 (CYP2D6, CYP2C9, CYP2C19, etc.). Enzymes from this family contribute to inter-individual differences in drug concentration in the plasma. The effects of polymorphisms in the CYP P450, range from an ineffective drug therapy to severe toxicity it can cause (e.g. drugs with a narrow therapeutic range (e.g., Warfarin) in patients with a reduced activity of CYP P450). Pharmacogenetic testing is carried out for a number of reasons: for selecting patients most likely to achieve therapeutic efficacy, in order to reduce side effects and determine the most appropriate dose, in order to achieve efficiency and a higher degree of therapy safety. The advantage of pharmacogenetic testing is reflected in the fact that it can be applied prior to drug application. Pharmacogenetics should satisfy patients' need for an effective therapy without side effects, physicians' need for assistance in selecting an adequate remedy and dosage for a particular patient, as well as other health care professionals, government agencies and pharmacists' needs.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Dragović, G., Dolić, N., Dimitrijević, B., Jovanović, M., Barović, M., & Jevtović, D. (2015). Pharmacogenetics in clinical practice: Challenges and opportunities. Medicinska istrazivanja, 49(3), 26–32. https://doi.org/10.5937/medist1501026d

MLA 9

Dragović, Gordana, et al. “Pharmacogenetics in clinical practice: Challenges and opportunities.” Medicinska istrazivanja, vol. 49, no. 3, 2015, pp. 26–32. https://doi.org/10.5937/medist1501026d.

Chicago

Dragović, Gordana, Nada Dolić, Božana Dimitrijević, Milan Jovanović, Marko Barović, and Djordje Jevtović. 2015. “Pharmacogenetics in clinical practice: Challenges and opportunities.” Medicinska istrazivanja 49 (3): 26–32. https://doi.org/10.5937/medist1501026d.

Harvard

Dragović, G. et al. (2015) ‘Pharmacogenetics in clinical practice: Challenges and opportunities’, Medicinska istrazivanja, 49(3), pp. 26–32. doi:10.5937/medist1501026d.

IEEE

G. Dragović, N. Dolić, B. Dimitrijević, M. Jovanović, M. Barović, and D. Jevtović, “Pharmacogenetics in clinical practice: Challenges and opportunities,” Medicinska istrazivanja, vol. 49, no. 3, pp. 26–32, 2015, doi: 10.5937/medist1501026d.

BibTeX

@article{dragovic2015pharmacogenetics,
  title     = {{Pharmacogenetics in clinical practice: Challenges and opportunities}},
  author    = {Dragović, Gordana and Dolić, Nada and Dimitrijević, Božana and Jovanović, Milan and Barović, Marko and Jevtović, Djordje},
  journal   = {Medicinska istrazivanja},
  year      = {2015},
  volume    = {49},
  number    = {3},
  pages     = {26--32},
  doi       = {10.5937/medist1501026d},
  url       = {https://doi.org/10.5937/medist1501026d}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism

  • pharmacogenetics
  • pharmacogenomics
  • personalized medicine
  • interindividual variability
  • drug metabolism
  • cytochrome P450
  • CYP2D6
  • CYP2C9

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Dragović, G., Dolić, N., Dimitrijević, B., Jovanović, M., Barović, M., & Jevtović, D. (2015). Pharmacogenetics in clinical practice: Challenges and opportunities. Medicinska istrazivanja, 49(3), 26–32. https://doi.org/10.5937/medist1501026d

How many times has this paper been cited?

0 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Medicinska istrazivanja: sign in and open the full text from this page.

Who wrote this paper?

Gordana Dragović, Nada Dolić, Božana Dimitrijević, Milan Jovanović, Marko Barović, Djordje Jevtović.

What is the DOI of this paper?

10.5937/medist1501026d, permanently at https://doi.org/10.5937/medist1501026d. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.